Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 6, 2002, Pages 501-508

  Papadopoulou, Maria V ^a   Ji, Ming ^a   Ji, Xinhai ^a   Bloomer, William D ^a   Hollingshead, Melinda G ^b  

^a Radiation Medicine Institute   (United States)

^b DTP   (United States)

Author keywords

Combined therapy; Human xenografts; Hypoxic cytotoxins; Murine tumors; NLCQ 1; Paclitaxel

Indexed keywords

4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; CYTOTOXIN; DRUG VEHICLE; NLCQ 1; PACLITAXEL; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GROWTH RETARDATION; HUMAN; HUMAN CELL; HYPOXIA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TOXICITY; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED C3H; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; QUINOLINES; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0036452676     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0521-8     Document Type: Article

References (56)

1. Aboagye EO, Maxwell RJ, Kelson AB, Tracy M, Lewis AD, Graham MA, Horsman MR, Griffiths JR, Workman P (1997) Preclinical evaluation of fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for measurement of tumor hypoxia. Cancer Res 57:3314
2. Blumenthal RD, Taylor A, Osorio L, Ochakovskaya R, Raleigh J, Papadopoulou M, Bloomer WD, Goldenberg DM (2001) Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int J Cancer 94:564
3. DM, Rosner GL, Harrelson J, Prosnitz LR, Dewhirst MW (1994) Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30:635
4. Brown JM (2000) Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol Med Today 6:157
5. Denny WA, Wilson WR, Atwell GJ, Boyd M, Pullen SM, Anderson RF (1991) Nitroacridines and nitroquinolines as DNA-affinic hypoxia-selective cytotoxins. In: Adams GE (ed) Activation of drugs by redox processes. NATO Advanced Study Series, pp 149-158
6. Dorie MJ, Brown JM (1993) Tumor-specific, schedule-dependent interaction between tirapazamine (SR4233) and cisplatin. Cancer Res 53:4633
7. Dorie MJ, Brown JM (1997) Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 39:361
8. Dorr RT, Snead K, Liddil JD (1996) Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 78:152
9. Durand RE, Raleigh JA (1998) Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res 58:3547
10. Etlinger DS (1993) Overview of paclitaxel (paclitaxel) in advanced lung cancer. Semin Oncol 20:46
11. Forastiere AA (1993) Use of paclitaxel (paclitaxel) in squamous cell carcinoma of the head and neck. Semin Oncol 20:56
12. Friery OP, Gallagher R, Murray MM, Hughes CM, Galligan ES, Mclntyre IA, Patterson LH, McKeown SR (2000) Enhancement of the anti-tumor effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br J Cancer 82:1469
13. Gallagher R, Hughes CM, Murray MM, Friery OP, Patterson LH, Hirst DG, McKeown SR (2001) The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 85:625
14. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3 Part 3:51
15. Grau C, Overgaard J (1988) Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13:301
16. Hay MP, Wilson WR, Moselen JW, Palmer BD, Denny WA (1994) Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: A new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. J Med Chem 37:381
17. Hicks KO, Fleming Y, Siim BG, Koch CJ, Wilson WR (1998) Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys 42:641
18. Hirst DG, Brown JM, Hazlehurst JL (1983) Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res 43:1961
19. 2 tension measurements. Cancer Res 51:6098
20. Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P (1996) Hypoxia and radiation response in human tumors. Semin Radiat Oncol 6:3
21. Holden SA, Teicher BA, Ara G, Herman TS, Coleman CN (1992) Enhancement of alkylating agent activity by SR-4233 in FSaIIC murine fibrosarcoma. J Natl Cancer Inst 84:187
22. Langmuir VK, Rooker JA, Osen M, Mendonca HL, Laderoute KR (1994) Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res 54:2845
23. Lartigau E, Guichard M (1996) The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumors. Br J Cancer 73:1480
24. Lartigau E, Le Ridant A-M, Lambin P, Weeger P, Martin L, Sigal R, Lusinchi A, Luboinski B, Eschwege F, Guichard M (1993) Oxygenation of head and neck tumors. Cancer 71:2319
25. Leith JT, Quaranto L, Padfield G, Michelson S, Hercbergs A (1993) Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: X-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo. Int J Radiat Oncol Biol Phys 25:283
26. McGuire WP, Rowinsky EK, Rosenshine NB, Grumbine FC, Ettingger DS, Armstrong DK, Donehower RC (1989) Paclitaxel: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273
27. Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R, Kris MG (1997) Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 8:1269
28. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L (1996) Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88:1308
29. Movsas B, Chapman JD, Horwitz EM, et al (1999) Hypoxic regions exist in human prostate carcinoma. Urology 53:11
30. 31PNMR for non-invasive evaluation of tumor metabolic status. Int J Radiat Oncol Biol Phys 12:93
31. Papadopoulou MV, Miller A, Seskey T, Epperly MW, Bloomer WD (1993) Potentiation of antineoplastic drugs in vitro and in vivo by intercalating bioreductive agents. Radiat Oncol Investig 1:206
32. Papadopoulou MV, Rosenzweig HS, Doddi M, Bloomer WD (1994) 9-[3-(2-Nitro-1-imidazolyl)-propylamino]-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol Res 6:439
33. Papadopoulou MV, Ji M, Rao MK, Bloomer WD (1996) 9-[3-(2-Nitro-1-imidazolyl)-propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol Res 8:425
34. Papadopoulou MV, Ji M, Bloomer WD (1996) THNLA-1 as radio/chemosensitizer of EMT6 tumors in mice. Br J Cancer 74 [Suppl XXVII]:S267
35. Papadopoulou MV, Ji M, Bloomer WD (1996) THNLA-1: A DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. In Vivo 10:49
36. Papadopoulou MV, Ji M, Rao MK, Bloomer WD (1997) 9-[3-(2-Nitro-1-imidazolyl)-propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): A novel DNA-affinic bioreductive agent as chemosensitizer. I. Oncol Res 9:249
37. Papadopoulou MV, Ji M, Bloomer WD (1998) NLCQ-1, a novel hypoxic cytotoxin: Potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int J Radiat Oncol Biol Phys 42:775
38. Papadopoulou MV, Ji M, Rao MK, Bloomer WD (2000) 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 12:185
39. Papadopoulou MV, Ji M, Rao MK, Bloomer WD (2000) 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent as radiosensitizer in vitro and in vivo. Comparison with tirapazamine. Oncol Res 12:325
40. Papadopoulou MV, Ji M, Bloomer WD (2001) Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother Pharmacol 48:160
41. Papadopoulou MV, Ji X, Bloomer WD (2001) Mechanisms involved in the potentiation of paclitaxel or 5-FU by the hypoxic cytotoxin NLCQ-1. Clinical Cancer Res [Suppl] 7:3679
42. Papadopoulou MV, Ji M, Bloomer WD (2002) Synergistic enhancement of the antitumor effect of taxol by the bioreduc-tive compound NLCQ-1, in vivo: Comparison with tirapazamine. Oncol Res 13:47-54
43. Papadopoulou MV, Ji X, Bloomer WD (2002) Hypoxia-dependent retinal toxicity of NLCQ-1 and tirapazamine in BALB/c mice (abstract 1092). Proceedings of the American Association for Cancer Research, vol 43
44. Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC (1997) Human tumor xenograft models in NCI drug development. In: Teicher B (ed) Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Humana Press, Totowa, pp 101-125
45. 18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36:417
46. Siemann DW (1984) Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys 10:1585
47. Siemann DW (1995) Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. Radiother Oncol 34:47
48. Siemann DW (1996) The in situ tumor response to combinations of cyclophosphamide and tirapazamine. Br J Cancer 74 [Suppl XXVII]:S65
49. Squillace DP, Ruben SL, Reid JM, Ames MM (2000) HPLC analysis and murine pharmacokinetics of the cytotoxic bioreductive agent NLCQ-1 (NSC 709257) (abstract 706). Proceedings of the American Association for Cancer Research, vol 41
50. Stratford IJ, Workman P (1998) Bioreductive drugs into the next millennium. Anticancer Drug Des 13:519
51. Teicher BA, Rose CM (1984) Perfluorochemical emulsions can increase tumor radiosensitivity. Science 223:934
52. Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriquez R, Drobins P, Miller W Jr, Meehan L, McKeon A, Devin J, von Roemeling R, Viallet J (1998) Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 16:3524
53. 2 tension measurements. Cancer Res 51:3316
54. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the International CATAPULT I Study Group. J Clin Oncol 18:1351
55. Wilson WR, Denny WA (1992) DNA-binding nitroheterocycles as hypoxia-selective cytotoxins. In: Dewey WC, Edington M, Fry RJM, Hall EJ Whitmore GF (eds) Radiation research: A 20th-century perspective, vol 2. Academic Press, New York, pp 796-801
56. Zaider M (1990) Concepts for describing the interaction of two agents. Radiat Res 123:257